

SINGLE TOPIC WORKSHOP PROGRAMME

- ▶ HCC surveillance – current recommendations and supporting evidence
- ▶ Limitations of HCC surveillance test effectiveness
- ▶ HCC surveillance utilization and interventions to increase use
- ▶ Precision screening for HCC: Is it possible and what do we need?
- ▶ Risk stratification biomarkers – are we close?
- ▶ Risk stratification after resection: Can we tailor surveillance for recurrence
- ▶ HCC chemoprevention: Current options and the horizon
- ▶ Phases of biomarker validation
- ▶ Emerging serum biomarkers for early HCC detection
- ▶ cfDNA for early HCC detection
- ▶ Alternative imaging modalities for HCC surveillance
- ▶ Bench to bedside: commercialization of biomarkers (industry representative)

This workshop is special as this is **ILCA's inaugural Single Topic Workshop (STW)**. We have chosen the topic of **prevention, risk stratification, and early detection** as these areas arguably have the **greatest potential** to reduce HCC-related mortality. We will discuss **recent advances** in each of these areas as well as areas in need of **continued research**.

Dr. Amit Singal

STW Co-Chair
UT Southwestern Medical Center, USA

Dr. Tim Meyer

STW Co-Chair
UCL Cancer Institute, University College
London, UK



WHAT

- **Understand** at-risk patients and current recommendations for **HCC surveillance**
- **Identify** barriers to HCC surveillance and potential strategies to **improve surveillance** effectiveness
- **Describe** proven as well as promising chemoprevention **strategies** for HCC in patients with cirrhosis



WHO

Clinical and translational **researchers, clinicians** (primarily GI/hepatology), and **industry representatives** interested in **HCC prevention, early detection** or biomarkers.

Talks may have **Western focus** (cirrhosis instead of HBV) although can interest delegates from **Asia**.

Single Topic Workshop is about:

The past few years have seen **significant changes** in the management of liver cancer and the Single Topic Workshop initiative was established in recognition of the rapidly **changing therapeutic landscape**. Each STW will focus on a specific area in which **recent developments** have transformed the field of HCC. ILCA aims to provide delegates with **state-of-the-art lectures** delivered by **leading experts** and anticipate that these meetings will be of interest to all disciplines engaged in delivering care to patients with liver cancer.

SPONSORSHIP OFFER (PARIS STW)

STW PARTNER
20,000 EUR

Acknowledgment

- ▶ **Before the event:**
 - Logo and company name on all printed material and on event website
 - Banner on an e-mail program (or similar) announcement to the delegates
- ▶ **During the event:**
 - Logo and company name on board or banner in registration area
 - Logo and company name on intermission slide during the workshop program
 - Logo and company name in program (brochure or App)
- ▶ **After the event:**
 - Logo and company name on 'thank you' e-mail to the delegates
- ▶ **Table top**
An equipped table top of 4 square meters:
 - Frame wall 2 x 2 meters high with printed canvas
 - Area finished in carpet
 - Electrical installation with electrical box with 500 w plug
 - Lighting with one adjustable spotlight
 - Reception desk
 - 2 stools

- Two complimentary registrations
- ILCA App Virtual delegate bag insert

STW SUPPORTER
10,000 EUR

Acknowledgment

- ▶ **Before the event:**
 - Company name on all STW material and on event website
- ▶ **During the event:**
 - Company name on board or banner in registration area
 - Company name on intermission slide during the workshop program
 - Company name in program (brochure or App)
- ▶ **After the event:**
 - Company name on 'thank you' e-mail to the delegates
- One complimentary registration

STW expected delegates:
150 participants

Contact us

Rik Bollaert
Sponsorship & Exhibition Manager
rik.bollaert@ilca-online.org

www.ilca-online.org

We would like to **thank all the sponsoring organizations** and hope you **enjoy the workshop!**